These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 1475036)

  • 1. Effect of imipramine treatment on heart rate variability measures.
    Yeragani VK; Pohl R; Balon R; Ramesh C; Glitz D; Weinberg P; Merlos B
    Neuropsychobiology; 1992; 26(1-2):27-32. PubMed ID: 1475036
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical experiments in maintenance and discontinuation of imipramine therapy in panic disorder with agoraphobia.
    Mavissakalian M; Perel JM
    Arch Gen Psychiatry; 1992 Apr; 49(4):318-23. PubMed ID: 1558466
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Specific side effects of long-term imipramine management of panic disorder.
    Mavissakalian M; Perel J; Guo S
    J Clin Psychopharmacol; 2002 Apr; 22(2):155-61. PubMed ID: 11910260
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gauging the effectiveness of extended imipramine treatment for panic disorder with agoraphobia.
    Mavissakalian MR; Perel JM; Talbott-Green M; Sloan C
    Biol Psychiatry; 1998 Jun; 43(11):848-54. PubMed ID: 9611676
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular variability in major depressive disorder and effects of imipramine or mirtazapine (Org 3770).
    Tulen JH; Bruijn JA; de Man KJ; Pepplinkhuizen L; van den Meiracker AH; Man in 't Veld AJ
    J Clin Psychopharmacol; 1996 Apr; 16(2):135-45. PubMed ID: 8690829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of imipramine treatment on changes in heart rate and blood pressure during postural and isometric handgrip tests.
    Yeragani VK; Meiri P; Balon R; Pohl R; Golec S
    Eur J Clin Pharmacol; 1990; 38(2):139-44. PubMed ID: 2338110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heart rate variability in patients with major depression.
    Yeragani VK; Pohl R; Balon R; Ramesh C; Glitz D; Jung I; Sherwood P
    Psychiatry Res; 1991 Apr; 37(1):35-46. PubMed ID: 1862160
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The side effects burden of extended imipramine treatment of panic disorder.
    Mavissakalian MR; Perel JM
    J Clin Psychopharmacol; 2000 Oct; 20(5):547-55. PubMed ID: 11001240
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Avoidance behaviour: a predictor of the efficacy of pharmacotherapy in panic disorder?
    Maier W; Roth SM; Argyle N; Buller R; Lavori P; Brandon S; Benkert O
    Eur Arch Psychiatry Clin Neurosci; 1991; 241(3):151-8. PubMed ID: 1790160
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blood pressure and heart rate response of panic disorder patients receiving imipramine in a dose-response treatment paradigm.
    de Groot CM; Mavissakalian MR
    J Clin Psychopharmacol; 1994 Apr; 14(2):107-10. PubMed ID: 8195450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The treatment of panic disorder in a clinical setting: a 12-month naturalistic study.
    Marchesi C; Ampollini P; Signifredi R; Maggini C
    Neuropsychobiology; 1997; 36(1):25-31. PubMed ID: 9211441
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Panic disorder with or without concomitant depression 5 years after treatment: a prospective follow-up.
    Albus M; Scheibe G; Scherer J
    J Affect Disord; 1995 May; 34(2):109-15. PubMed ID: 7665802
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Maintenance drug therapy of panic disorder.
    Curtis GC; Massana J; Udina C; Ayuso JL; Cassano GB; Perugi G
    J Psychiatr Res; 1993; 27 Suppl 1():127-42. PubMed ID: 8145175
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of the Panic and Agoraphobia Scale in a clinical trial.
    Bandelow B; Brunner E; Broocks A; Beinroth D; Hajak G; Pralle L; Rüther E
    Psychiatry Res; 1998 Jan; 77(1):43-9. PubMed ID: 10710174
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Three-year follow-up of patients with panic disorder after short-term treatment with alprazolam and imipramine.
    Lepola UM; Rimón RH; Riekkinen PJ
    Int Clin Psychopharmacol; 1993; 8(2):115-8. PubMed ID: 8345160
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decreased heart rate variability in panic disorder patients: a study of power-spectral analysis of heart rate.
    Yeragani VK; Pohl R; Berger R; Balon R; Ramesh C; Glitz D; Srinivasan K; Weinberg P
    Psychiatry Res; 1993 Jan; 46(1):89-103. PubMed ID: 8464959
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of imipramine, fluvoxamine and depressive mood on autonomic cardiac functioning in major depressive disorder.
    Volkers AC; Tulen JH; van den Broek WW; Bruyn JA; Passchier J; Pepplinkhuizen L
    Pharmacopsychiatry; 2004 Jan; 37(1):18-25. PubMed ID: 14750044
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imipramine treatment of panic disorder with agoraphobia: dose ranging and plasma level-response relationships.
    Mavissakalian MR; Perel JM
    Am J Psychiatry; 1995 May; 152(5):673-82. PubMed ID: 7726306
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Duration of imipramine therapy and relapse in panic disorder with agoraphobia.
    Mavissakalian MR; Perel JM
    J Clin Psychopharmacol; 2002 Jun; 22(3):294-9. PubMed ID: 12006900
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of panic disorder.
    Cassano GB; Toni C; Musetti L
    Adv Biochem Psychopharmacol; 1992; 47():449-60. PubMed ID: 1509926
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.